chloroquinehydroxychloroquin
recent
subject
intens
debat
regard
potenti
antivir
activ
etiolog
agent
report
possibl
cur
effect
other
order
shed
light
rather
controversi
topic
use
mathemat
model
simul
possibl
scenario
respons
hydroxychloroquin
patient
computeraid
simul
show
hydroxychloroquin
may
impact
amplitud
viral
load
peak
viral
clearanc
significantli
acceler
drug
administ
earli
enough
ie
viral
load
rang
copiesml
although
author
use
trough
plasma
concentr
theoret
drug
distribut
lung
model
effect
chloroquinehydroxychloroquin
theoret
drug
respons
base
trough
whole
blood
concentr
drug
agre
well
result
clinic
trial
far
report
moreov
effect
chloroquinehydroxychloroquin
could
fulli
explain
take
account
also
capac
drug
rais
cellmedi
respons
product
cell
whole
present
studi
suggest
chloroquinehydroxychloroquin
narrow
therapeut
window
overlap
highest
toler
dose
consider
may
implic
develop
combin
therapi
prevent
strategi
chloroquin
hydroxyanalog
hydroxychloroquin
first
propos
treatment
sever
acut
respiratori
syndrom
sar
due
promis
invitro
effect
repurpos
drug
treatment
clinic
trial
far
produc
mix
result
studi
interact
drug
virushost
dynam
vivo
necessari
order
provid
insight
optim
time
administr
associ
intervent
howev
mani
decad
clinic
use
hydroxychloroquin
part
pharmacokinet
still
unknown
number
studi
still
reli
drug
plasma
concentr
optim
indic
biodistribut
drug
weak
base
becom
readili
entrap
intracellular
acid
organel
due
hendersonhasselbach
law
recent
advanc
like
shed
light
interplay
antivir
drug
avail
mathemat
model
abl
simul
virushost
interplay
match
clinic
observ
similar
model
develop
author
studi
proven
abl
simul
viral
dynam
hivaid
provid
import
therapeut
hint
present
paper
use
model
simul
possibl
scenario
respons
hydroxychloroquin
patient
present
paper
use
system
differenti
equat
built
et
al
follow
ordinari
differenti
equat
describ
viral
dynam
model
target
cell
popul
eclips
phase
account
antivir
effect
chloroquin
viral
reproduct
target
cell
popul
repres
target
cell
assum
base
assumpt
ml
nasopharyng
volum
maintain
cellular
concentr
cellsml
becom
infect
constant
paramet
chang
accord
constant
paramet
reflect
antivir
effect
chloroquin
simul
base
assumpt
reduct
viral
basic
reproduct
number
r
antivir
repres
infect
cell
eclips
phase
repres
product
infect
cell
start
product
phase
averag
time
k
valu
consid
allow
predict
intervent
time
effect
viral
propag
releas
virion
control
constant
paramet
p
chang
accord
constant
paramet
assum
default
infect
cell
later
clear
constant
paramet
rate
c
assum
follow
previou
model
viral
infect
infect
cell
clear
later
circul
constant
rate
assum
default
v
reflect
viral
popul
model
chang
v
copiesml
mathemat
model
implement
use
python
program
languag
v
http
wwwpythonorg
odeint
function
scipi
packag
use
solv
ordinari
differenti
equat
numer
solut
appli
numpi
packag
simul
plot
within
day
time
frame
use
matplotlib
packag
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
advanc
stage
simul
start
viral
load
copiesml
provid
consid
unrealist
use
system
differenti
equat
develop
et
al
show
hydroxychloroquin
may
impact
amplitud
viral
load
peak
effect
viral
clearanc
evid
simul
mild
viral
load
less
pronounc
viral
load
viral
rna
copiesml
ie
viral
load
commonli
found
throat
swab
symptomat
diseas
use
paramet
adopt
author
model
show
earli
peak
viral
replic
follow
gradual
slow
abat
viral
load
accompani
consumpt
target
cell
figur
supplement
figur
first
row
treatment
simul
et
al
conclud
hydroxychloroquin
suffici
effect
viral
load
dynam
pharmacokinet
paramet
use
conduct
simul
plasma
drug
concentr
mention
unlik
reflect
biodistribut
drug
light
plasma
concentr
invivo
drug
efficaci
calcul
second
row
figur
supplement
figur
show
simul
condit
use
whole
blood
concentr
includ
drug
compart
entrap
lysosom
calcul
drug
efficaci
base
concentrationrespons
curv
publish
yao
et
al
case
pronounc
decreas
viral
peak
observ
figur
supplement
figur
third
row
anoth
aspect
need
attent
doubl
mechan
antivir
effect
hydroxychloroquin
deriv
studi
huge
number
virus
lysosom
entrap
hydroxychloroquin
highli
like
affect
viral
entri
simul
et
al
postentri
stage
cellular
organel
viral
bud
viral
particl
glycosyl
consid
aforement
studi
accord
data
wang
et
al
chloroquin
display
approxim
half
antivir
activ
ad
viru
adsorpt
onto
cell
confirm
part
activ
occur
postentri
level
therefor
also
want
estim
impact
hydroxychloroquineinduc
impair
viral
product
time
beyond
h
period
consid
estim
hydroxychloroquin
efficaci
vitro
decreas
viral
product
rate
ie
half
valu
calcul
basi
drug
efficaci
whole
viral
replic
cycl
obtain
decreas
viral
load
peak
steadyst
figur
fourth
row
data
use
estim
respons
hydroxychloroquin
base
trough
blood
concentr
provid
morita
et
al
base
drug
regimen
mgday
gautret
et
al
recent
publish
trough
serum
concentr
hydroxychloroquin
obtain
patient
treat
higher
dosag
ie
mgday
hydroxychloroquin
unfortun
blood
concentr
report
gautret
et
al
could
proport
deriv
ratio
provid
morita
et
al
maintain
similar
plasmablood
concentr
ratio
calcul
led
predict
drug
level
whole
blood
plot
valu
doserespons
curv
publish
yao
et
al
extrapol
efficaci
adjust
viral
infect
product
accordingli
obtain
decreas
viral
load
peak
figur
supplement
figur
fifth
row
simul
may
also
account
hydroxychloroquin
administ
mgday
combin
anoth
antivir
agent
moder
potenc
among
immunemodul
effect
hydroxychloroquin
capac
induc
antigen
crosspresent
increas
immun
cytotox
respons
enhanc
cytotox
respons
result
increas
death
infect
cell
increas
death
rate
product
infect
cell
effect
cytotox
immun
fold
data
deriv
accapezzato
et
al
could
observ
decreas
peak
amplitud
shorter
time
viral
load
exhaust
figur
supplement
figur
sixth
row
simul
provid
confirm
current
hypothes
virolog
respons
hydroxychloroquin
patient
pharmacokinet
basi
drug
dosag
accept
toxic
profil
narrow
window
overlap
antivir
effect
concentr
result
line
previou
analys
hiv
clinic
trial
show
dosag
adopt
safe
clinic
lowest
rang
therapeut
window
signific
though
yet
partial
effect
observ
highest
dose
administ
observ
line
clinic
data
report
far
small
trial
franc
suggest
hydroxychloroquin
help
treat
small
studi
china
report
opposit
result
studi
limit
limit
statist
power
due
fact
prepar
emerg
discrep
result
obtain
may
resid
accord
result
present
studi
dosag
hydroxychloroquin
adopt
french
studi
report
posit
result
use
mgday
hydroxychloroquin
chines
studi
unabl
show
efficaci
follow
adopt
lower
dosag
mgday
furthermor
report
respons
hydroxychloroquin
french
studi
incomplet
author
add
anoth
experiment
drug
reposit
antivir
azithromycin
order
increas
efficaci
consider
line
result
obtain
random
clinic
trial
use
chloroquin
hydroxychloroquin
equival
dosag
superior
report
two
aforement
studi
safeti
margin
chloroquinehydroxychloroquin
narrow
administr
higher
dosag
unfortun
hamper
toxic
shown
borba
et
al
although
recent
data
show
toxic
observ
borba
et
al
could
fact
ascrib
concomit
administr
azithromycin
result
agre
part
simul
conduct
arnold
buckner
show
mgday
regimen
might
signific
impact
viral
replic
accord
paramet
adopt
garciacremad
et
al
show
dosag
higher
equal
mgday
necessari
obtain
sustain
remiss
approach
follow
conserv
adopt
arnold
buckner
use
whole
blood
concentr
measur
predict
tissu
accumul
rather
predict
accumul
lung
accord
model
adopt
arnold
buckner
drug
lung
concentr
hundr
time
higher
plasma
predict
reach
concentr
abl
inhibit
percent
replic
decid
follow
predict
tissu
accumul
hydroxychloroquin
lung
mainli
driven
tissu
macrophag
main
target
viru
accord
data
publish
yao
et
al
per
cent
inhibit
coronaviru
replic
reachabl
experiment
use
hydroxychloroquin
also
smit
et
al
reach
similar
conclus
base
pharmacokinet
consider
base
simul
suggest
chloroquin
may
silver
bullet
erad
infect
side
might
display
benefici
effect
vivo
simul
go
beyond
model
publish
indic
earlier
virolog
negativ
expect
hydroxychloroquin
administ
dosag
mgday
dosag
mgday
iewithin
narrow
therapeut
window
instead
believ
theoret
capac
hydroxychloroquin
decreas
viral
load
peak
viral
replic
activ
deserv
attent
investig
result
simul
line
recent
meta
analysi
far
avail
clinic
data
show
hydroxychloroquin
may
decreas
diseas
sever
viral
clearanc
administ
symptomat
patient
one
limit
present
studi
resid
fact
model
viral
dynam
effect
molecul
immun
mediat
mechan
cytokin
storm
may
impact
immun
hyperactiv
case
infer
estim
potenti
drug
decreas
viral
load
peak
amplitud
associ
deleteri
immun
hyperactiv
coronaviru
infect
hypothesi
line
abil
infect
tcell
target
cell
hiv
character
immun
hyperactiv
well
final
show
effect
chloroquinehydroxychloroquin
antigen
crosspresent
consid
crosspresent
phenomenon
dendrit
cell
present
antigen
tcell
improv
prime
activ
tcell
prime
antigen
recognit
induc
select
kill
infect
cell
take
account
paramet
possibl
predict
hydroxychloroquin
may
acceler
viral
clearanc
administ
earli
accordingli
model
scenario
increas
cellmedi
respons
viral
load
higher
immun
dysregul
case
like
taken
place
enhanc
cellmedi
respons
may
induc
select
kill
infect
cell
also
enhanc
immun
better
longterm
control
infect
hydroxychloroquin
current
investig
also
prophylact
agent
given
great
interest
strategi
far
evok
context
futur
vaccin
diseas
consid
coadministr
chloroquinehydroxychloroquin
case
chloroquinehydroxychloroquin
prove
ineffect
protect
acquisit
plausibl
may
mitig
diseas
sever
attenu
viral
replic
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
